EA201990560A1 - Композиции, содержащие тритерпеноиды, и их применение для лечения оптической нейропатии - Google Patents

Композиции, содержащие тритерпеноиды, и их применение для лечения оптической нейропатии

Info

Publication number
EA201990560A1
EA201990560A1 EA201990560A EA201990560A EA201990560A1 EA 201990560 A1 EA201990560 A1 EA 201990560A1 EA 201990560 A EA201990560 A EA 201990560A EA 201990560 A EA201990560 A EA 201990560A EA 201990560 A1 EA201990560 A1 EA 201990560A1
Authority
EA
Eurasian Patent Office
Prior art keywords
treatment
application
compositions containing
optical neuropathy
containing triterpenoids
Prior art date
Application number
EA201990560A
Other languages
English (en)
Inventor
Цадик Хазан
Андре К.Б. Лукассен
Константин Адамский
Original Assignee
Регенера Фарма Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Регенера Фарма Лтд. filed Critical Регенера Фарма Лтд.
Publication of EA201990560A1 publication Critical patent/EA201990560A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/569—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone substituted in position 17 alpha, e.g. ethisterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/11—Aldehydes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/22—Anacardiaceae (Sumac family), e.g. smoketree, sumac or poison oak
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Steroid Compounds (AREA)

Abstract

Настоящее изобретение относится к композициям и лекарственным формам, содержащим по меньшей мере одну тритерпеновую кислоту и по меньшей мере один нейтральный тритерпеноид, а также к их применению для лечения состояний оптической нейропатии.
EA201990560A 2016-09-08 2017-09-07 Композиции, содержащие тритерпеноиды, и их применение для лечения оптической нейропатии EA201990560A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662384717P 2016-09-08 2016-09-08
PCT/IL2017/051007 WO2018047175A1 (en) 2016-09-08 2017-09-07 Compositions comprising triterpenoids and uses thereof for treating optic neuropathy

Publications (1)

Publication Number Publication Date
EA201990560A1 true EA201990560A1 (ru) 2019-09-30

Family

ID=61562370

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201990560A EA201990560A1 (ru) 2016-09-08 2017-09-07 Композиции, содержащие тритерпеноиды, и их применение для лечения оптической нейропатии

Country Status (10)

Country Link
US (1) US11207333B2 (ru)
EP (1) EP3509699A4 (ru)
JP (1) JP7012379B2 (ru)
KR (1) KR20190050800A (ru)
CN (1) CN109906104A (ru)
AU (1) AU2017322653A1 (ru)
BR (1) BR112019004488A2 (ru)
CA (1) CA3036036A1 (ru)
EA (1) EA201990560A1 (ru)
WO (1) WO2018047175A1 (ru)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3099304A4 (en) 2014-01-31 2018-01-10 Mayo Foundation for Medical Education and Research Novel therapeutics for the treatment of glaucoma
CA2999820A1 (en) 2015-09-24 2017-03-30 Regenera Pharma Ltd. Compositions comprising triterpenoids
EP3509577A4 (en) * 2016-09-08 2020-04-08 Regenera Pharma Ltd. COMPOSITION WITH ACID EXTRACTS FROM RUBBER FITTING AND USES THEREOF FOR TREATING OPTICAL NEUROPATHY
CN115768419A (zh) * 2020-02-07 2023-03-07 奎拉里斯生物公司 用于色满卡林前药治疗的改进方法和组合物
KR102585191B1 (ko) * 2020-08-25 2023-10-04 경기대학교 산학협력단 신규한 벤조디아제핀-3-온 유도체 및 이를 포함하는 당뇨병성 신경병증 치료 또는 예방용 약학적 조성물

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004518707A (ja) 2001-02-13 2004-06-24 イサム・リサーチ・デベロツプメント・カンパニー・オブ・ザ・ヘブルー・ユニバーシテイ・オブ・エルサレム カロテノイドを充填されたリポソーム
AU2003241345A1 (en) * 2002-05-01 2003-11-17 Lavipharm S.A. Use of mastic and its components for the control of microbial infections
US20050074509A1 (en) 2003-10-02 2005-04-07 Data Medica Padova S.P.A. Cancer treatment using natural plant products or essential oils extracted from some pistacia species or components
FR2867980B1 (fr) 2004-03-23 2006-07-14 Pierre Fabre Medicament Sa Utilisation de l'acide masticadienonique en tant qu'inhibiteur de l'adn polymerase beta
WO2005112967A2 (en) 2004-05-19 2005-12-01 Balfour Marketing Corp. Anticancer activity of chios mastic gum
EP3578191A1 (en) 2009-03-04 2019-12-11 Regenera Pharma Ltd. Compositions of polymeric myrcene
ES2617875T3 (es) 2009-03-04 2017-06-20 Regenera Pharma Ltd. Usos terapéuticos de masilla de goma
WO2011130302A2 (en) * 2010-04-12 2011-10-20 Reata Pharmaceuticals, Inc. Method of treating obesity using antioxidant inflammation modulators
BR122019022461B1 (pt) * 2010-09-07 2022-03-15 Regenera Pharma Ltd Processo para preparar uma fração ácida isolada de goma mástique
US20150246087A1 (en) 2012-06-11 2015-09-03 Regenera Pharma Ltd. Extracts and therapeutic uses thereof
CN103656290B (zh) 2013-12-11 2015-07-01 张有富 一种治疗视神经萎缩的药物及其制备方法
ES2896173T3 (es) 2014-02-13 2022-02-24 Katairo Gmbh Procedimientos para la determinación de compuestos o composiciones para el tratamiento de enfermedades relacionadas con la lipofuscina y compuestos o composiciones
CA2941970A1 (en) 2014-03-13 2015-09-17 Retrotope, Inc. Optic neuropathy treatment and reduction of steroid-induced oxidative stress with stabilized polyunsaturated substances
IL237621A0 (en) 2015-03-08 2015-06-30 Regenera Pharma Ltd Use of isolated fractions of the gum goddess to treat optic neuropathy

Also Published As

Publication number Publication date
US20190224217A1 (en) 2019-07-25
BR112019004488A2 (pt) 2019-05-28
JP7012379B2 (ja) 2022-01-28
AU2017322653A1 (en) 2019-04-04
KR20190050800A (ko) 2019-05-13
CA3036036A1 (en) 2018-03-15
JP2019526590A (ja) 2019-09-19
EP3509699A1 (en) 2019-07-17
WO2018047175A1 (en) 2018-03-15
EP3509699A4 (en) 2020-05-06
US11207333B2 (en) 2021-12-28
CN109906104A (zh) 2019-06-18

Similar Documents

Publication Publication Date Title
EA201990495A1 (ru) Биарильные соединения, применимые в качестве иммуномодуляторов
EA201990560A1 (ru) Композиции, содержащие тритерпеноиды, и их применение для лечения оптической нейропатии
EA201792354A1 (ru) Композиции обетихолевой кислоты и способы применения
EA201990221A1 (ru) 1,3-дигидроксифенильные производные, применимые в качестве иммуномодуляторов
EA201790806A1 (ru) Иммунорегулирующие средства
EA201891083A1 (ru) Составы антител к cd38 для подкожного введения и их применение
EA201892147A1 (ru) Бициклические соединения
EA201691259A1 (ru) РЕГУЛЯТОРЫ Nrf2
EA201790998A1 (ru) Иммуннорегуляторные агенты
EA201890204A1 (ru) Антибактериальные соединения
EA201990043A1 (ru) Антибактериальные соединения
EA201790273A1 (ru) Флагеллиновые композиции и их применение
EA201691070A1 (ru) Новые трициклические соединения в качестве противораковых средств
EA201792047A1 (ru) Новые соединения
EA201890052A1 (ru) Регуляторы nrf2
EA201592143A1 (ru) Новые бициклические ингибиторы бромодомена
EA201890858A1 (ru) 2,4-дигидроксиникотинамиды как агонисты apj
EA201591746A1 (ru) Способы и композиции для ингибирования бромодомен-содержащих белков
EA201692526A1 (ru) Замещенные [1,2,4]триазольные соединения
EA201890247A1 (ru) Ингибиторы дезоксиуридинтрифосфатазы, содержащие гидантоин
EA201890592A1 (ru) Жидкие фармацевтические композиции, содержащие ингибиторы sglt-2
EA201892225A1 (ru) АНТИТЕЛА К ФАКТОРУ Bb КОМПЛЕМЕНТА И ИХ ПРИМЕНЕНИЕ
EA201890767A1 (ru) C4-модифицированные производные олеаноловой кислоты для ингибирования il-17 и других применений
EA201990257A1 (ru) Фракции плазмы крови в качестве лечения когнитивных расстройств, связанных со старением
EA201691141A1 (ru) Соединения против ccr6